-
Mashup Score: 1Miami Myeloma MRD Meeting 2023 - HealthTree for Myeloma - 1 year(s) ago
The Miami Myeloma MRD 2023 Virtual Meeting takes place on 6th April 2023 at 9am – 1pm EST
Source: healthtree.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Months after the FDA granted accelerated approval to dostarlimab for this rectal cancer indication, phase 2 data have confirmed its efficacy and safety.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Maged Khalil, MD, discussed historic issues with treating #MRD, locally advanced rectal cancer, and the subgroups in the most need for new treatment options. #crcsm | @MSKCancerCenter https://t.co/xCjvdQpy7i
-
-
Mashup Score: 3MRD2STOP research update - HealthTree for Myeloma - 1 year(s) ago
The MRD2STOP research shows promise for a potential end to maintenance.
Source: healthtree.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @clonoSEQ: Myeloma patients and caregivers, read about #MRD-guided therapy in this #ASH22 trial, #MRD2STOP. https://t.co/2vRk40rktp #mms…
-
-
Mashup Score: 0
Recorded on February 23rd, 2023 as part of the Minimal Residual Disease Chapter in the Myeloma Community Program by HealthTree with Dr. Marc Braunstein.The …
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
I enjoyed talking about #MRD in #myeloma with the community at @HealthTreeMM @Perlmutter_CC https://t.co/lEt4PZBvVh
-
-
Mashup Score: 0The Multiple Myeloma Daily - 1 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/pNBkBvc3EG Thanks to @docbraunstein #mrd #myeloma
-
-
Mashup Score: 0
Should all regimens’ end goal be to achieve MRD negativity? Dr. Marc Braunstein answers your questions.
Source: healthtree.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
I'm looking forward to speaking with the community at @HealthTreeMM this Thursday on #MRD testing in #myeloma. #mmsm @Perlmutter_CC https://t.co/zoV9m7LlbO
-
-
Mashup Score: 0MRD-guided therapy in patients with intermediate-risk AML compared to unguided cohort using PSM - 1 year(s) ago
Jesse Tettero, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, shares the findings of a study investigating measurable residual disease (MRD)-guided…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jesse Tettero (@amsterdamumc) shares the results of a study investigating MRD-guided therapy in patients with intermediate-risk AML: 👉 https://t.co/3Nm8nCRTdA 👈 #LeuSM #HemOnc #AMLsm #MRD
-
-
Mashup Score: 0
Blood Podcast – Season 5, Episode 6 | Blood | American Society of Hematology MRD dynamics during ixazomib maintenance in MM, disparities in CAR T-cell therapy for ALL, and BAX variants and resistance to BH3-mimetics in AML In this week’s episode, we’ll discuss the dynamics of measurable residual disease, or MRD, over time in myeloma patients undergoing ixazomib maintenance….
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New episode this week includes topics on #MRD dynamics during ixazomib maintenance in MM, disparities in CAR T-cell therapy for #ALL, and BAX variants and resistance to BH3-mimetics in #AML https://t.co/38yXL4uehY https://t.co/UgazQTDlpt
-
-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigators in a new study utilized an “add-on” time-limited treatment approach for patients with #CLL with detectable minimal residual disease #MRD who received treatment with ibrutinib monotherapy in the frontline or relapsed/refractory settings: https://t.co/Nt2Rwy4I4a https://t.co/7o071Y83OZ
-
-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigators in a new study utilized an “add-on” time-limited treatment approach for patients with #CLL with detectable minimal residual disease #MRD who received treatment with ibrutinib monotherapy in the frontline or relapsed/refractory settings: https://t.co/Nt2Rwy4I4a https://t.co/OY1SUbXEr8
-
RT @HealthtreeMM: #MRD workshop hosted by @SylvesterCancer @DrOlaLandgren. Event details and registration here: https://t.co/kH3CRIgxlE…